Time-Resolved scRNA-Seq Tracks the Adaptation of a Sensitive MCL Cell Line to Ibrutinib Treatment

Since the approval of ibrutinib for relapsed/refractory mantle cell lymphoma (MCL), the treatment of this rare mature B-cell neoplasm has taken a great leap forward. Despite promising efficacy of the Bruton tyrosine kinase inhibitor, resistance arises inevitably and the underlying mechanisms remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Fuhr, Viktoria, Vafadarnejad, Ehsan, Dietrich, Oliver, Arampatzi, Panagiota, Riedel, Angela, Saliba, Antoine-Emmanuel, Rosenwald, Andreas, Rauert-Wunderlich, Hilka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956352/
https://www.ncbi.nlm.nih.gov/pubmed/33668876
http://dx.doi.org/10.3390/ijms22052276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956352/
https://www.ncbi.nlm.nih.gov/pubmed/33668876
http://dx.doi.org/10.3390/ijms22052276

Ejemplares similares